Oppenheimer Cuts enGene (NASDAQ:ENGN) Price Target to $30.00

enGene (NASDAQ:ENGN) had its target price reduced by Oppenheimer from $33.00 to $30.00 in a research report released on Wednesday morning,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

A number of other research firms have also recently issued reports on ENGN. Weiss Ratings restated a “sell (d-)” rating on shares of enGene in a report on Friday, January 9th. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of enGene in a research report on Monday, March 9th. Citizens Jmp increased their target price on shares of enGene from $18.00 to $21.00 and gave the stock a “market outperform” rating in a research note on Wednesday, November 12th. Morgan Stanley raised their price target on shares of enGene from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Wednesday, November 12th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of enGene in a research note on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.86.

enGene Stock Down 1.9%

Shares of NASDAQ:ENGN opened at $7.16 on Wednesday. enGene has a 1 year low of $2.65 and a 1 year high of $12.25. The company has a debt-to-equity ratio of 0.09, a current ratio of 11.75 and a quick ratio of 6.30. The business’s 50-day moving average is $9.39 and its 200-day moving average is $8.12. The company has a market capitalization of $479.65 million, a price-to-earnings ratio of -3.18 and a beta of -0.29.

enGene (NASDAQ:ENGN) last released its earnings results on Monday, March 9th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.11. Equities research analysts predict that enGene will post -1.56 earnings per share for the current year.

Hedge Funds Weigh In On enGene

Institutional investors have recently modified their holdings of the company. Cresset Asset Management LLC bought a new position in shares of enGene in the 2nd quarter worth $36,000. Affinity Asset Advisors LLC bought a new stake in enGene during the 2nd quarter valued at $280,000. Paloma Partners Management Co bought a new stake in enGene during the 2nd quarter valued at $38,000. PFS Partners LLC acquired a new position in enGene during the third quarter worth $61,000. Finally, Raymond James Financial Inc. lifted its stake in shares of enGene by 383.6% in the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after buying an additional 7,932 shares in the last quarter. 64.16% of the stock is owned by institutional investors and hedge funds.

enGene News Summary

Here are the key news stories impacting enGene this week:

• Positive Sentiment: Strong clinical progress for lead candidate detalimogene voraplasmid — a 63% complete response rate at 3 months in NMIBC, favorable tolerability, and pivotal cohort enrollment above targets. Management plans a LEGEND cohort update at a spring medical conference and expects a BLA submission in H2 2026, which are clear binary catalysts that could drive the stock if results and the regulatory pathway remain favorable. enGene Holdings: Key Catalysts Incoming For 2026
• Positive Sentiment: HC Wainwright raised EPS forecasts across multiple 2026–2029 periods and reiterated a “Buy” rating with a $25 price target — the analyst cut loss expectations (improved EPS) for FY2026–2029 and lifted near‑term quarter forecasts, signaling improved underlying assumptions about development progress and cash runway that can support a higher valuation if milestones are met. MarketBeat: HC Wainwright raises estimates for enGene
• Neutral Sentiment: Industry/sector noise unrelated to enGene — coverage about automakers phasing out V6 engines is not relevant to ENGN’s biotech story and is unlikely to affect the stock’s near-term performance. Why Automakers Are Phasing Out V6 Engines
• Negative Sentiment: Valuation and execution risk remain — consensus still anticipates continued losses (negative EPS), the company must deliver confirmatory pivotal data and a successful BLA, and the stock is trading below its 50‑day moving average, leaving downside if upcoming updates disappoint or timelines slip. enGene profile and metrics

enGene Company Profile

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.